ONCSM.E — Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapHigh Flyer

Market Cap
TRY5.82bn
Enterprise Value
TRY5.86bn
Revenue
TRY709.08m

Annual income statement for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS, fiscal year end - December 31st, TRY millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	R2023 December 31st	R2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	128	293	347	490	709
Cost of Revenue
Gross Profit	88.3	101	51.7	181	320
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	55.9	258	439	482	555
Operating Profit	72.1	34.8	-92	8.06	154
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	80.4	-2.5	-136	-66.5	73.4
Provision for Income Taxes
Net Income After Taxes	71.7	-20.8	-115	-77.4	50.4
Minority Interest
Net Income Before Extraordinary Items
Net Income	71.7	-20.8	-115	-77.4	50.4
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	71.7	-20.8	-115	-77.4	50.4
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.62	-0.794	-4.87	-3.25	2.07
Dividends per Share